A notable accessory screening program for detection of cervical intraepithelial neoplasia

H. T. Tsai, Y. M. Tsai, S. F. Yang, C. H. Lee, L. Y. Lin, S. Lee, M. T. Wu

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: Papanicolaou (Pap) smear test is implemented to detect cervical intraepithelial neoplasia (CIN) in Taiwan. However, the utility of that has limitations. High-risk human papillomavirus (HR-HPV) is an important risk factor in development of cervical cancer. In this study, we estimate the utility of HR-HPV testing in the screening of CIN. Methods: Firstly, 726 subjects were recruited and willing to prove cervical exfoliated epithelial cells for Pap smear screening and HR-HPV DNA testing. Subsequently, 205 of the eligible subjects with greater than or equal to CIN1 of Pap smear results were asked to perform histologic diagnosis that served as a gold standard for the estimation of the effects of both Pap smear and HR-HPV testing. Results: The histology is significantly associated with HR-HPV infection, as well as significantly highly correlated with the individuals who have both Pap smear greater than or equal to CIN1 and positive HR-HPV infection but not significantly correlated with the individuals who only have Pap smear greater than or equal to CIN1 but without HR-HPV infection. Conclusions: Combinative surveillance of HR-HPV infection and Pap smear is a useful tool to detect and monitor precancerous lesions in the screening program. HR-HPV testing is a notable accessory screening program for detection of CIN in Taiwanese women.

Original languageEnglish
Pages (from-to)477-482
Number of pages6
JournalPathologie Biologie
Volume57
Issue number6
DOIs
Publication statusPublished - Sep 2009

Fingerprint

Cervical Intraepithelial Neoplasia
Papanicolaou Test
Accessories
Screening
Papillomavirus Infections
Testing
Histology
Taiwan
Uterine Cervical Neoplasms
Epithelial Cells
DNA

Keywords

  • Cervical intraepithelial neoplasia (CIN)
  • High-risk human papillomavirus (HR-HPV)
  • Hybrid Capture II (HCII)
  • Papanicolaou (Pap) smear

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

A notable accessory screening program for detection of cervical intraepithelial neoplasia. / Tsai, H. T.; Tsai, Y. M.; Yang, S. F.; Lee, C. H.; Lin, L. Y.; Lee, S.; Wu, M. T.

In: Pathologie Biologie, Vol. 57, No. 6, 09.2009, p. 477-482.

Research output: Contribution to journalArticle

Tsai, H. T. ; Tsai, Y. M. ; Yang, S. F. ; Lee, C. H. ; Lin, L. Y. ; Lee, S. ; Wu, M. T. / A notable accessory screening program for detection of cervical intraepithelial neoplasia. In: Pathologie Biologie. 2009 ; Vol. 57, No. 6. pp. 477-482.
@article{7595f5876dad45bf8697b03152cf4bbb,
title = "A notable accessory screening program for detection of cervical intraepithelial neoplasia",
abstract = "Objective: Papanicolaou (Pap) smear test is implemented to detect cervical intraepithelial neoplasia (CIN) in Taiwan. However, the utility of that has limitations. High-risk human papillomavirus (HR-HPV) is an important risk factor in development of cervical cancer. In this study, we estimate the utility of HR-HPV testing in the screening of CIN. Methods: Firstly, 726 subjects were recruited and willing to prove cervical exfoliated epithelial cells for Pap smear screening and HR-HPV DNA testing. Subsequently, 205 of the eligible subjects with greater than or equal to CIN1 of Pap smear results were asked to perform histologic diagnosis that served as a gold standard for the estimation of the effects of both Pap smear and HR-HPV testing. Results: The histology is significantly associated with HR-HPV infection, as well as significantly highly correlated with the individuals who have both Pap smear greater than or equal to CIN1 and positive HR-HPV infection but not significantly correlated with the individuals who only have Pap smear greater than or equal to CIN1 but without HR-HPV infection. Conclusions: Combinative surveillance of HR-HPV infection and Pap smear is a useful tool to detect and monitor precancerous lesions in the screening program. HR-HPV testing is a notable accessory screening program for detection of CIN in Taiwanese women.",
keywords = "Cervical intraepithelial neoplasia (CIN), High-risk human papillomavirus (HR-HPV), Hybrid Capture II (HCII), Papanicolaou (Pap) smear",
author = "Tsai, {H. T.} and Tsai, {Y. M.} and Yang, {S. F.} and Lee, {C. H.} and Lin, {L. Y.} and S. Lee and Wu, {M. T.}",
year = "2009",
month = "9",
doi = "10.1016/j.patbio.2008.05.006",
language = "English",
volume = "57",
pages = "477--482",
journal = "Current Research in Translational Medicine",
issn = "2452-3186",
publisher = "Elsevier Masson",
number = "6",

}

TY - JOUR

T1 - A notable accessory screening program for detection of cervical intraepithelial neoplasia

AU - Tsai, H. T.

AU - Tsai, Y. M.

AU - Yang, S. F.

AU - Lee, C. H.

AU - Lin, L. Y.

AU - Lee, S.

AU - Wu, M. T.

PY - 2009/9

Y1 - 2009/9

N2 - Objective: Papanicolaou (Pap) smear test is implemented to detect cervical intraepithelial neoplasia (CIN) in Taiwan. However, the utility of that has limitations. High-risk human papillomavirus (HR-HPV) is an important risk factor in development of cervical cancer. In this study, we estimate the utility of HR-HPV testing in the screening of CIN. Methods: Firstly, 726 subjects were recruited and willing to prove cervical exfoliated epithelial cells for Pap smear screening and HR-HPV DNA testing. Subsequently, 205 of the eligible subjects with greater than or equal to CIN1 of Pap smear results were asked to perform histologic diagnosis that served as a gold standard for the estimation of the effects of both Pap smear and HR-HPV testing. Results: The histology is significantly associated with HR-HPV infection, as well as significantly highly correlated with the individuals who have both Pap smear greater than or equal to CIN1 and positive HR-HPV infection but not significantly correlated with the individuals who only have Pap smear greater than or equal to CIN1 but without HR-HPV infection. Conclusions: Combinative surveillance of HR-HPV infection and Pap smear is a useful tool to detect and monitor precancerous lesions in the screening program. HR-HPV testing is a notable accessory screening program for detection of CIN in Taiwanese women.

AB - Objective: Papanicolaou (Pap) smear test is implemented to detect cervical intraepithelial neoplasia (CIN) in Taiwan. However, the utility of that has limitations. High-risk human papillomavirus (HR-HPV) is an important risk factor in development of cervical cancer. In this study, we estimate the utility of HR-HPV testing in the screening of CIN. Methods: Firstly, 726 subjects were recruited and willing to prove cervical exfoliated epithelial cells for Pap smear screening and HR-HPV DNA testing. Subsequently, 205 of the eligible subjects with greater than or equal to CIN1 of Pap smear results were asked to perform histologic diagnosis that served as a gold standard for the estimation of the effects of both Pap smear and HR-HPV testing. Results: The histology is significantly associated with HR-HPV infection, as well as significantly highly correlated with the individuals who have both Pap smear greater than or equal to CIN1 and positive HR-HPV infection but not significantly correlated with the individuals who only have Pap smear greater than or equal to CIN1 but without HR-HPV infection. Conclusions: Combinative surveillance of HR-HPV infection and Pap smear is a useful tool to detect and monitor precancerous lesions in the screening program. HR-HPV testing is a notable accessory screening program for detection of CIN in Taiwanese women.

KW - Cervical intraepithelial neoplasia (CIN)

KW - High-risk human papillomavirus (HR-HPV)

KW - Hybrid Capture II (HCII)

KW - Papanicolaou (Pap) smear

UR - http://www.scopus.com/inward/record.url?scp=69649086264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69649086264&partnerID=8YFLogxK

U2 - 10.1016/j.patbio.2008.05.006

DO - 10.1016/j.patbio.2008.05.006

M3 - Article

C2 - 18586410

AN - SCOPUS:69649086264

VL - 57

SP - 477

EP - 482

JO - Current Research in Translational Medicine

JF - Current Research in Translational Medicine

SN - 2452-3186

IS - 6

ER -